

The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



天津泰達生物醫學工程股份有限公司
Tianjin TEDA Biomedical Engineering Company Limited
(a joint stock company incorporated in the People's Republic of China with limited liability)
(Stock code: 8189)

PROPOSED CHANGE IN USE OF PROCEEDS

References are made to the announcements of Tianjin TEDA Biomedical Engineering Company Limited (the “**Company**”) dated 16 January 2025, 5 February 2025, 9 February 2025, 10 February 2025 and 19 February 2025 (the “**Announcements**”) in relation to, among other things, the Placing and the use of proceeds. Unless otherwise defined, capitalised terms used herein have the same meanings as defined in the Announcements.

CHANGE IN USE OF PROCEEDS

As stated in the announcement of the Company dated 19 February 2025, a total of 135,900,000 Placing Shares have been successfully placed by the Placing Agent to not less than six Placees at the New Placing Price of HK\$0.375 per Placing Share pursuant to the terms and conditions of the Placing Agreements, raising approximately HK\$50.96 million. The net proceeds after deduction of commission and other expenses of the Placing amounted to approximately HK\$50.50 million. As of the date of this announcement, the Company has not utilised such proceeds.

According to the announcement of the Company dated 16 January 2025, the proceeds of the Placing will be used as follows:

The Company intends to utilise the net proceeds to incorporate a new company together with our business partners to acquire a medical health software platform from Yi Tunnel (Beijing) Technology Co., Ltd. to meet the elderly care needs of the elderly population, including health monitoring, chronic disease management and professional nursing etc., and thereby advancing the current medical and elderly care health business of the Company. Yi Tunnel (Beijing) Technology Co., Ltd. is a high-tech enterprise in Beijing, focusing on the integration of computer vision and AI big data, promoting the digital and intelligent upgrading of the industry, with artificial intelligence technology as the core, committed to the application of technology in practical scenarios. It is one of Nvidia’s cloud service provider partners in Mainland China. The incorporation of the new company may constitute a notifiable transaction of the Company and the Company will comply with all necessary Listing Rules in due course including issue of any announcements and obtain shareholders approval if required.

After prudent consideration and detailed evaluation of the Group's operation and business strategies, the Board has resolved to change the use of the proceeds as follows:

The proceeds will be used for the acquisition of an artificial intelligence-based medical health software platform, as well as for the subsequent development of the medical health software platform, general working capital for the medical and elderly care health business and potential investment opportunities.

REASONS FOR AND BENEFITS OF THE CHANGE IN USE OF PROCEEDS

In summary, the original use of proceeds can be described to acquire an artificial intelligence-based medical health software platform, thereby advancing the current medical and elderly care health business of the Company. After prudent consideration and detailed evaluation of the Company's operation and business strategies, the Board has resolved to adjust part of the proceeds from the Placing for the subsequent development of the medical health software platform, general working capital for the medical and elderly care health business and potential investment opportunities, in addition to the acquisition of a medical health software platform.

As the Company makes intensive efforts in the development of the medical and elderly care health sector, the purchase of the medical health software platform alone can no longer satisfy the demand for a comprehensive layout. Adjusting part of the proceeds for the subsequent development of the medical health software platform will help upgrade and optimise the functions of the software platform so as to better advance the medical and elderly care health business; adjusting part of the proceeds for the general working capital of the medical and elderly care health business will help promote the marketing of the medical health software platform; and adjusting part of the proceeds for potential investment opportunities in the medical and elderly care health business will enable the Company to cope with market changes and seize opportunities that are conducive to the Company's long-term development in a more flexible manner.

The Board believes that the reasonable allocation of the proceeds to the acquisition of a medical health software platform, the subsequent development of the medical health software platform, general working capital for the medical and elderly care health business and potential investment opportunities can avoid the concentration of proceeds on a single purpose which may result in idle funds, deploy the financial resources more effectively and enhance the business performance of the Group in the long run, and therefore is in the interests of the Group and its shareholders as a whole.

The Company will update its shareholders on the progress of the utilisation of the net proceeds through disclosures in its annual report and interim report. The Board will continue to monitor the use of the net unutilised proceeds and may modify or amend the plans for such use as and when necessary so as to respond to the market condition and endeavour to improve the business performance of the Group.

By order of the Board
Tianjin TEDA Biomedical Engineering Company Limited
Sun Li
Chairman

Tianjin, the PRC
20 March 2025

As at the date of this announcement, the executive directors of the Company are Ms. Sun Li and Mr. He Xin; the non-executive directors of the Company are Mr. Cao Aixin, Dr. Li Ximing and Ms. Li Xueying; the independent non-executive directors of the Company are Mr. Wang Yongkang, Ms. Gao Chun and Mr. Tu Xiangzhen.

This announcement, for which the directors are willing to collectively and individually accept full responsibility, includes particulars given in compliance with the GEM Listing Rules for the purpose of giving information with regard to the Company. The directors of the Company, having made all reasonable enquiries, confirm that to the best of their knowledge and belief that the information contained in this announcement is accurate and complete in all material respects and is not misleading or deceptive, and there are no other matters the omission of which would make any statement herein or this announcement misleading.

This announcement will remain on the GEM website at www.hkgem.com on the “Latest Listed Company Information” page for 7 days from the date of its posting, and it will also be published and remain on the website of the Company at www.bioteda.com.